Eli Lilly has more to offer than some investors realize.

Lilly agreed to purchase biotech Orna Therapeutics. Orna's drug candidate treats diseases in a novel way. Lilly has been busy this year filling its drug pipeline. 10 stocks we like better than Eli ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month. The partnership between Eli Lilly ...

Eli Lilly and Co. (NYSE: LLY) on Tuesday today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The synthetic medicine active pharmaceutical ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...

Eli Lilly's stock has skyrocketed in value due to the success of its popular GLP-1 products. Analysts project upside of around 17% for the stock in the near term. The healthcare stock's high valuation ...

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...

Eli Lilly's fourth-quarter revenue rose by 43%, largely a result of its impressive GLP-1 products. Sales from its GLP-1 drugs doubled, and they are key components of the company's business. The stock ...